Condition: Urothelial Carcinoma (UC) · Bladder (Urothelial, Transitional Cell) Cancer · Liquid Biopsy · Sponsor: Tianjin Medical University Second Hospital
Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma
This description comes directly from the study's public registry record.
Hailong Hu, MD · +8613662096232 · huhailong@tmu.edu.cn
Always discuss trial participation with your own doctor first.
| The second hospital of Tianjin Medical University | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07441499